Relationship Between Circulating Tumor Cells Undergoing EMT and Short-term Efficacy Following Interventional Treatment in Patients with Hepatocellular Carcinoma

Overview

Journal J Interv Med

Specialty General Medicine

Date 2021 Nov 22

PMID 34805926

Citations 5

Authors

Meng Chen

Rongde Xu

Lingeng Wu

Xiaoming Chen

Affiliations

Soon will be listed here.

Abstract

Objective: A growing number of studies have indicated that epithelial-mesenchymal transition (EMT) phenotypes and the number of circulating tumor cells (CTCs) are significant indicators of tumor characteristics and treatment efficacy, and thus have a broad range of potential applications in the diagnosis and treatment of malignant tumors. The value of data on CTC phenotypes and CTC counts in the diagnosis of hepatocellular carcinoma (HCC) and assessment of efficacy after comprehensive interventional therapy remains unclear.

Methods: Data of 107 patients who exhibited space-occupying lesions in the liver on enhanced CT/MRI scans at the Guangdong Provincial People's Hospital (a tertiary medical center) between August 2017 and October 2018, were retrospectively analyzed. All enrolled patients were treated with transcatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA). An imFISH CTC assay was used to isolate and count CTCs with different EMT phenotypes in the patients' peripheral blood, which facilitated an analysis of the value of CTC phenotype and CTC count data in the diagnosis or treatment of HCC.

Results: The CTC count and EMT phenotypes in HCC patients were not associated with patient characteristics such as age, sex, Hepatitis B Virus (HBV)-DNA status, alcohol consumption history, Aspartate Transaminase (AST) to Platelet Ratio Index (APRI) score, Eastern Cooperative Oncology Group (ECOG) score, Child-Pugh score, alpha-fetoprotein (AFP), number and size of tumors, vascular invasion, or metastasis (P > 0.05). The CTC count and EMT phenotypes in HCC patients before treatment were not predictive of short-term efficacy (P > 0.05). Comprehensive interventional therapy reduced the total CTC count and mesenchymal CTC count (P = 0.034 and 0.022, respectively).

Conclusion: TACE in combination with ablation reduced the total CTC count and mesenchymal CTC count. The CTC count and EMT phenotypes may be associated with long-term efficacy.

Citing Articles

Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer.

Jiang J, Mo W, Lian X, Cao D, Cheng H, Wang H Exp Ther Med. 2024; 28(1):294.

PMID: 38827467 PMC: 11140314. DOI: 10.3892/etm.2024.12583.

Preoperative Locoregional Therapy May Relate with Stemness and Distinct Transitions Between Epithelial and Mesenchymal States in Hepatocellular Carcinoma.

Espirito Santo J, Ladeirinha A, Alarcao A, Strelet E, Reis M, Santos R J Clin Exp Hepatol. 2023; 14(1):101268.

PMID: 38076372 PMC: 10709210. DOI: 10.1016/j.jceh.2023.08.004.

Liquid Biopsy in Hepatocellular Carcinoma: The Significance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Monitoring.

Shaik M, Sagar P, Shaik N, Randhawa N Int J Mol Sci. 2023; 24(13).

PMID: 37445822 PMC: 10341811. DOI: 10.3390/ijms241310644.

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer.

Xu Y, Ren X, Jiang T, Lv S, Gao K, Liu Y BMC Cancer. 2023; 23(1):475.

PMID: 37226235 PMC: 10207832. DOI: 10.1186/s12885-023-10979-z.

Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma.

Niu Z, Wang W, Niu X World J Gastroenterol. 2022; 28(46):6433-6477.

PMID: 36569275 PMC: 9782839. DOI: 10.3748/wjg.v28.i46.6433.

References

Wang S, Zheng Y, Liu J, Huo F, Zhou J . Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation. J Investig Med. 2018; 66(5):1-6. DOI: 10.1136/jim-2017-000655. View

Cheng B, Jia C, Liu C, Fan W, Wang Q, Zhang Z . Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008; 299(14):1669-77. DOI: 10.1001/jama.299.14.1669. View

Xue F, Shi S, Zhang Z, Xu C, Zheng J, Qin T . Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation. Oncol Lett. 2018; 15(4):5481-5488. PMC: 5840532. DOI: 10.3892/ol.2018.8019. View

Biederman D, Titano J, Bishay V, Durrani R, Dayan E, Tabori N . Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study. Radiology. 2016; 283(3):895-905. DOI: 10.1148/radiol.2016160718. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Wang Z, Luo L, Cheng Y, He G, Peng B, Gao Y . Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood. J Gastrointest Surg. 2017; 22(4):633-639. PMC: 5869875. DOI: 10.1007/s11605-017-3619-3. View

Cheng Y, Luo L, Zhang J, Zhou M, Tang Y, He G . Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma. J Gastrointest Surg. 2019; 23(12):2354-2361. DOI: 10.1007/s11605-018-04067-y. View

Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z . Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Sci Adv. 2019; 5(6):eaav4275. PMC: 6584608. DOI: 10.1126/sciadv.aav4275. View

Sun Y, Guo W, Xu Y, Shi Y, Gong Z, Ji Y . Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. Clin Cancer Res. 2017; 24(3):547-559. DOI: 10.1158/1078-0432.CCR-17-1063. View

10.

Shiha G, Ibrahim A, Helmy A, Sarin S, Omata M, Kumar A . Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2016; 11(1):1-30. DOI: 10.1007/s12072-016-9760-3. View

11.

Ogle L, Orr J, Willoughby C, Hutton C, McPherson S, Plummer R . Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?. J Hepatol. 2016; 65(2):305-13. DOI: 10.1016/j.jhep.2016.04.014. View

12.

Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S . Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers (Basel). 2019; 11(6). PMC: 6627043. DOI: 10.3390/cancers11060835. View

13.

Ye X, Li G, Han C, Han Q, Shang L, Su H . Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma. Cancer Manag Res. 2018; 10:5639-5647. PMC: 6245351. DOI: 10.2147/CMAR.S175489. View

14.

Dharan N, Neuhaus J, Rockstroh J, Peters L, Gordin F, Arenas-Pinto A . Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology. 2018; 69(3):1135-1150. PMC: 6393919. DOI: 10.1002/hep.30296. View

15.

Yu J, Xiao W, Dong S, Liang H, Zhang Z, Zhang B . Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer. 2018; 18(1):835. PMC: 6102841. DOI: 10.1186/s12885-018-4744-4. View

16.

Shen J, Wang W, Zhu X, Ni C . High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization. J Vasc Interv Radiol. 2018; 29(12):1678-1684. DOI: 10.1016/j.jvir.2018.07.030. View

17.

Xu R, Wei W, Krawczyk M, Wang W, Luo H, Flagg K . Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017; 16(11):1155-1161. DOI: 10.1038/nmat4997. View

18.

Liu Y, Hu B, Li Z, He X, Li Y, Lu L . An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int. 2016; 10(4):640-6. DOI: 10.1007/s12072-016-9732-7. View

19.

Xiao G, Yang J, Yan L . Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2014; 61(1):292-302. DOI: 10.1002/hep.27382. View

20.

Kanwal F, Kramer J, Asch S, Cao Y, Li L, El-Serag H . Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2019; 71(1):44-55. DOI: 10.1002/hep.30823. View